BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 21592673)

  • 1. Targeted therapies for advanced non-small-cell lung cancer: current status and future implications.
    Custodio A; Méndez M; Provencio M
    Cancer Treat Rev; 2012 Feb; 38(1):36-53. PubMed ID: 21592673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy.
    Rossi A; Maione P; Sacco PC; Ambrosio R; Falanga M; Gridelli C
    Curr Drug Targets; 2010 Jul; 11(7):865-8784. PubMed ID: 20412044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
    Maione P; Gridelli C; Troiani T; Ciardiello F
    Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current management of advanced non-small cell lung cancer: targeted therapy.
    Isobe T; Herbst RS; Onn A
    Semin Oncol; 2005 Jun; 32(3):315-28. PubMed ID: 15988686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent developments of targeted therapies in the treatment of non-small cell lung cancer.
    Rossi A; Maione P; Colantuoni G; Ferrara C; Rossi E; Guerriero C; Nicolella D; Falanga M; Palazzolo G; Gridelli C
    Curr Drug Discov Technol; 2009 Jun; 6(2):91-102. PubMed ID: 19519336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapies for advanced non-small cell lung cancer.
    Starakis I; Nikolakopoulos A; Mazokopakis EE
    Comb Chem High Throughput Screen; 2012 Sep; 15(8):641-55. PubMed ID: 22409867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
    Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
    Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
    Janning M; Loges S
    Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapies in lung cancer.
    Besse B; Ropert S; Soria JC
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix135-42. PubMed ID: 17631566
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeted therapies in lung cancer.
    Pirker R; Filipits M
    Curr Pharm Des; 2009; 15(2):188-206. PubMed ID: 19149612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.
    Nagano T; Tachihara M; Nishimura Y
    Curr Cancer Drug Targets; 2019; 19(8):595-630. PubMed ID: 30526458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies for non-small cell lung cancer.
    Dempke WC; Suto T; Reck M
    Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to EGF-R (erbB-1) and VEGF-R modulating agents.
    Dempke WCM; Heinemann V
    Eur J Cancer; 2009 May; 45(7):1117-1128. PubMed ID: 19124237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions.
    Ellis PM; Al-Saleh K
    Crit Rev Oncol Hematol; 2012 Oct; 84(1):47-58. PubMed ID: 22405734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better….
    Di Maio M; Morabito A; Piccirillo MC; Daniele G; Giordano P; Costanzo R; Sandomenico C; Montanino A; Rocco G; Perrone F
    Curr Pharm Des; 2014; 20(24):3901-13. PubMed ID: 24191956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
    Raben D; Helfrich B; Bunn PA
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
    Harichand-Herdt S; Ramalingam SS
    Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel targeted approaches in non-small cell lung cancer (NSCLC).
    Ardizzoni A; Tiseo M
    Ann Oncol; 2006 May; 17 Suppl 5():v91-3. PubMed ID: 16807473
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.
    Berge EM; Doebele RC
    Semin Oncol; 2014 Feb; 41(1):110-25. PubMed ID: 24565585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.